Insiders who reported open-market trades in the last 12 months at the companies George Kemble files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
David Happel - $562K in SGMT purchases and sales in the last 12 months
Elizabeth Rozek - $96K in SGMT purchases and sales in the last 12 months
George Kemble is a corporate insider, tracked as Director of Sagimet Biosciences Inc. (SGMT). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has George Kemble submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has George Kemble been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($4.22M) across all tracked filings.
George Kemble is Director of Sagimet Biosciences Inc. (SGMT). 5 SEC Form 4 filings on record going back to 2025, most recently on 17 August 2026. Most recent open-market trade: sold $3.59M of SGMT on 17 August 2026. Lifetime open-market sales: $4.22M.
Recent transactions
8
The latest 8 SEC Form 4 transactions reported by George Kemble.
InsiderAlpha's records for George Kemble go back to 2025: 5 primary Form 4 filings, an average of 2.5 per year. 12 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
